Toll Free: 1-888-928-9744

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016

Published: Apr 20, 2016 | Pages: 434 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016', provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Recurrent Glioblastoma Multiforme (GBM)
- The report reviews pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Recurrent Glioblastoma Multiforme (GBM) therapeutics and enlists all their major and minor projects
- The report assesses Recurrent Glioblastoma Multiforme (GBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Content 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Recurrent Glioblastoma Multiforme (GBM) Overview 9 Therapeutics Development 10 Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Overview 10 Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis 11 Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 12 Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 15 Recurrent Glioblastoma Multiforme (GBM) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Recurrent Glioblastoma Multiforme (GBM) - Products under Development by Companies 19 Recurrent Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 23 Recurrent Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 24 AbbVie Inc. 24 Agenus, Inc. 25 Amgen Inc. 26 AngioChem Inc. 27 Apogenix GmbH 28 AstraZeneca Plc 29 Axelar AB 30 BeiGene, Ltd. 31 Boehringer Ingelheim GmbH 32 Boston Biomedical, Inc. 33 Bristol-Myers Squibb Company 34 Cantex Pharmaceuticals, Inc. 35 Cavion LLC 36 Celldex Therapeutics, Inc. 37 Coherus BioSciences, Inc. 38 Cortice Biosciences, Inc. 39 Eisai Co., Ltd. 40 Eli Lilly and Company 41 EnGeneIC Ltd 42 ERC Belgium SA 43 GenSpera, Inc. 44 Genzyme Corporation 45 GW Pharmaceuticals Plc 46 ImmunoCellular Therapeutics, Ltd. 47 Karyopharm Therapeutics, Inc. 48 Les Laboratoires Servier SAS 49 Medicenna Therapeutics, Inc. 50 Merck & Co., Inc. 51 Novartis AG 52 Ono Pharmaceutical Co., Ltd. 53 Oryx GmbH & Co. KG 54 Pfizer Inc. 55 Stemline Therapeutics, Inc. 56 Threshold Pharmaceuticals, Inc. 57 Tocagen Inc. 58 TRACON Pharmaceuticals, Inc. 59 Vascular Biogenics Ltd. 60 Vaximm AG 61 Virttu Biologics Limited 62 Recurrent Glioblastoma Multiforme (GBM) - Therapeutics Assessment 63 Assessment by Monotherapy Products 63 Assessment by Combination Products 64 Assessment by Target 65 Assessment by Mechanism of Action 69 Assessment by Route of Administration 72 Assessment by Molecule Type 74 Drug Profiles 76 (GWP-42002 + GWP-42003) - Drug Profile 76 abemaciclib - Drug Profile 77 acalabrutinib - Drug Profile 79 afatinib dimaleate - Drug Profile 82 AMG-595 - Drug Profile 87 asinercept - Drug Profile 89 AU-101 - Drug Profile 91 AU-105 - Drug Profile 92 axitinib - Drug Profile 93 AXL-1717 - Drug Profile 97 AZD-7451 - Drug Profile 99 bevacizumab biosimilar - Drug Profile 100 BGB-290 - Drug Profile 101 bosutinib - Drug Profile 103 buparlisib hydrochloride - Drug Profile 106 capmatinib - Drug Profile 110 Cellular Immunotherapy for Recurrent Glioblastoma Multiforme - Drug Profile 113 Cellular Immunotherapy to Target Interleukein 13 Receptor Alpha-2 for Acute Myelocytic Leukemia and Glioblastoma Multiforme - Drug Profile 114 CX-02 - Drug Profile 115 dacomitinib - Drug Profile 116 dasatinib - Drug Profile 119 depatuxizumab mafodotin - Drug Profile 122 DNX-2401 - Drug Profile 124 ERC-1671 - Drug Profile 127 evofosfamide - Drug Profile 129 flucytosine ER + vocimagene amiretrorepvec - Drug Profile 137 G-200 - Drug Profile 140 galunisertib - Drug Profile 142 golvatinib + lenvatinib - Drug Profile 144 golvatinib tartrate - Drug Profile 146 HSV-1716 - Drug Profile 148 ICT-121 - Drug Profile 151 infigratinib - Drug Profile 153 lenvatinib mesylate - Drug Profile 154 lonafarnib - Drug Profile 160 MDNA-55 - Drug Profile 162 mibefradil dihydrochloride - Drug Profile 163 mipsagargin - Drug Profile 165 nabiximols - Drug Profile 167 napabucasin - Drug Profile 171 NEO-100 - Drug Profile 174 nilotinib - Drug Profile 176 nivolumab - Drug Profile 180 ofranergene obadenovec - Drug Profile 188 ONC-201 - Drug Profile 190 Oncolytic Virus for Oncology - Drug Profile 193 Oncolytic Virus to Target Carcinoembryonic Antigen for Oncology - Drug Profile 194 Oncolytic Virus to Target IL-12 for Oncology - Drug Profile 196 OS-2966 - Drug Profile 197 p28 - Drug Profile 198 paclitaxel trevatide - Drug Profile 200 Parvoryx - Drug Profile 202 pazopanib hydrochloride - Drug Profile 203 pembrolizumab - Drug Profile 209 ramucirumab - Drug Profile 219 rilotumumab - Drug Profile 225 rindopepimut - Drug Profile 227 S-49076 - Drug Profile 229 selinexor - Drug Profile 230 SGT-53 - Drug Profile 236 SL-701 - Drug Profile 238 sonidegib phosphate - Drug Profile 240 TPI-287 - Drug Profile 244 TRC-102 - Drug Profile 247 trebananib - Drug Profile 249 vandetanib - Drug Profile 252 VEDVDox - Drug Profile 258 vorinostat - Drug Profile 259 VXM-01 - Drug Profile 263 Recurrent Glioblastoma Multiforme (GBM) - Recent Pipeline Updates 265 Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects 415 Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products 417 Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones 418 Featured News & Press Releases 418 Appendix 428 Methodology 428 Coverage 428 Secondary Research 428 Primary Research 428 Expert Panel Validation 428 Contact Us 428 Disclaimer 429
List of Tables
Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H1 2016 15 Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H1 2016 16 Number of Products under Development by Companies, H1 2016 17 Number of Products under Development by Companies, H1 2016 (Contd..1) 18 Number of Products under Development by Companies, H1 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Late Stage Development, H1 2016 21 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Development, H1 2016 23 Products under Development by Companies, H1 2016 24 Products under Development by Companies, H1 2016 (Contd..1) 25 Products under Development by Companies, H1 2016 (Contd..2) 26 Products under Development by Companies, H1 2016 (Contd..3) 27 Products under Investigation by Universities/Institutes, H1 2016 28 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc., H1 2016 29 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H1 2016 30 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H1 2016 31 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc., H1 2016 32 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H1 2016 33 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H1 2016 34 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H1 2016 35 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by BeiGene, Ltd., H1 2016 36 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 37 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical, Inc., H1 2016 38 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H1 2016 39 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals, Inc., H1 2016 40 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H1 2016 41 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics, Inc., H1 2016 42 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences, Inc., H1 2016 43 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences, Inc., H1 2016 44 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co., Ltd., H1 2016 45 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H1 2016 46 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H1 2016 47 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H1 2016 48 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GenSpera, Inc., H1 2016 49 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corporation, H1 2016 50 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H1 2016 51 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2016 52 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 53 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H1 2016 54 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics, Inc., H1 2016 55 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co., Inc., H1 2016 56 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H1 2016 57 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 58 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co. KG, H1 2016 59 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H1 2016 60 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics, Inc., H1 2016 61 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 62 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc., H1 2016 63 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 64 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd., H1 2016 65 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H1 2016 66 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Limited, H1 2016 67 Assessment by Monotherapy Products, H1 2016 68 Assessment by Combination Products, H1 2016 69 Number of Products by Stage and Target, H1 2016 71 Number of Products by Stage and Mechanism of Action, H1 2016 75 Number of Products by Stage and Route of Administration, H1 2016 78 Number of Products by Stage and Molecule Type, H1 2016 80 Recurrent Glioblastoma Multiforme (GBM) Therapeutics - Recent Pipeline Updates, H1 2016 270 Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2016 420 Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H1 2016 421 Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products, H1 2016 422


List of Figures
Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H1 2016 15 Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H1 2016 16 Number of Products under Development by Companies, H1 2016 17 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Clinical Stage Development, H1 2016 22 Assessment by Monotherapy Products, H1 2016 68 Assessment by Combination Products, H1 2016 69 Number of Products by Top 10 Targets, H1 2016 70 Number of Products by Stage and Top 10 Targets, H1 2016 70 Number of Products by Top 10 Mechanism of Actions, H1 2016 74 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 74 Number of Products by Top 10 Routes of Administration, H1 2016 77 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 77 Number of Products by Top 10 Molecule Types, H1 2016 79 Number of Products by Stage and Top 10 Molecule Types, H1 2016 79

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealan

Read More...

Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among ot

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify